Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PDUFA IV Is “Golden Opportunity” To Improve Drug Safety Funding And Staff

Executive Summary

The current round of reauthorization of the Prescription Drug User Fee Act presents a "golden opportunity" to improve FDA's regulation of drug safety, according to the Institute of Medicine's Assessment of the U.S. Drug Safety System Committee

You may also be interested in...



FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor

A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism

FDA’s Risk/Benefit Decisions Will Be Quantified With Metric From Contractor

A recent request for proposals may signal a shift in FDA's approach to risk/benefit analysis and views on outcome measures, a move some see as bringing more transparency while also shielding the agency from criticism

FDA PDUFA Performance Hampered By Inadequate Staffing – OND’s Jenkins

Staffing issues are affecting FDA performance goals as the agency enters the fourth iteration of the Prescription Drug User Fee Act

Related Content

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel